Baird Maintains Outperform on Warby Parker, Lowers Price Target to $30

Baird analyst Mark Altschwager maintains Warby Parker (NYSE:WRBY) with a Outperform and lowers the price target from $40 to $30.

byBenzinga Newsdesk

May 17, 2022

1 minute read

Baird analyst Mark Altschwager maintains Warby Parker (NYSE:WRBY) with a Outperform and lowers the price target from $40 to $30.

News

Looking Into Nordstrom’s Return On Capital Employed

By Benzinga Insights

Today, 5:49 AM

Nordstrom (NYSE:JWN) reported Q1 sales of $2.92 billion. Earnings fell to a loss of $85.00 million, resulting in a 383.33% decrease from last quarter. In Q4, Nordstrom earned $30.00 million, and total sales reached $3.65 billion.

JWN

Deutsche Bank Maintains Hold on Teladoc Health, Lowers Price Target to $27

By Benzinga Newsdesk

Today, 5:49 AM

Deutsche Bank analyst George Hill maintains Teladoc Health (NYSE:TDOC) with a Hold and lowers the price target from $31 to $27.

TDOC

64 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:49 AM

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the company filed a mixed shelf offering on Friday after the close.

ABVC

FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate

By Vandana Singh

Today, 5:49 AM

The FDA issued a Complete Response Letter to Cytokinetics Incorporated’s (NASDAQ:CYTK) omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for…

CYTK

Baird Maintains Outperform on Warby Parker, Lowers Price Target to $30

Related Posts

Looking Into Nordstrom’s Return On Capital Employed

Deutsche Bank Maintains Hold on Teladoc Health, Lowers Price Target to $27

64 Biggest Movers From Yesterday

FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate